Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.
about
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futureProfile of efraloctocog alfa and its potential in the treatment of hemophilia A.Changing paradigm of prophylaxis with longer acting factor concentrates.Innovative approach for improved rFVIII concentrate.Predictors of non-adherence to prescribed prophylactic clotting-factor treatment regimens among adolescent and young adults with a bleeding disorder.Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice.Practical aspects of extended half-life products for the treatment of haemophilia
P2860
Q26853631-23B70E2D-B348-4352-B481-1D861ECAFE22Q35565320-A3FB71F5-4893-4A26-8893-738C6538A9DEQ38206858-753645AE-5ABF-420E-84E3-E53809B86F94Q38207134-01683EBE-E7DE-4595-AC75-72906831F8BFQ40739601-75E3E518-5446-4ABE-A8AA-B3275811EF8EQ54965788-3E9A6051-EE13-4A82-A66E-E4118FB8037DQ58761664-7AEB0DF4-E6DC-4434-AB39-E93C68538854
P2860
Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel coagulation factor conce ...... laxis in haemophilia patients.
@en
type
label
Novel coagulation factor conce ...... laxis in haemophilia patients.
@en
prefLabel
Novel coagulation factor conce ...... laxis in haemophilia patients.
@en
P2093
P2860
P356
P1433
P1476
Novel coagulation factor conce ...... laxis in haemophilia patients.
@en
P2093
B Sørensen
G Auerswald
V Jiménez-Yuste
P2860
P304
P356
10.1111/HAE.12094
P577
2013-02-06T00:00:00Z